|
Real-time Estimate
Cboe BZX
20:00:00 2026-09-16 EDT
|
5-day change | 1st Jan Change | ||
| 144.40 USD | -0.66% |
|
+5.77% | +366.31% |
| 09-16 | Moderna Insider Sold Shares Worth $11,691,420, According to a Recent SEC Filing | MT |
| 09-16 | Ebola response making progress in Congo, but outbreak 'far from over,' WHO says | RE |
| Market Cap | 58.13B 50.38B 47.62B 43.23B 81.02B 5,577B 81.5B 568B 220B 2,829B 218B 214B 9,016B | P/E 2026 * |
-17.4x | P/E 2027 * | -30.4x |
|---|---|---|---|---|---|
| Enterprise Value | 54.48B 47.21B 44.62B 40.51B 75.93B 5,226B 76.38B 533B 206B 2,651B 205B 200B 8,450B | EV / Sales 2026 * |
25.9x | EV / Sales 2027 * | 23x |
| Free-Float |
92.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Tradegate
| 0QF | Real-time | |
|
Xetra
| 0QF | Delayed | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
Boerse Muenchen
| 0QF | Real-time | |
|
CBOE
| Real-time | ||
|
Swiss Exchange
| MRNA | Delayed | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
London S.E.
| 0A45 | Delayed | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Lima
| MRNAUS | End-of-day quote | |
|
CBOE
| 0A45 | Real-time | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript: Moderna, Inc.
| 1 day | -0.66% | ||
| 1 week | +5.77% | ||
| Current month | +2.18% | ||
| 1 month | +127.32% | ||
| 3 months | +161.00% | ||
| 6 months | +173.32% | ||
| Current year | +366.31% |
| 1 week | 135.9 |  | 148.07 |
| 1 month | 62.56 | | 165 |
| Current year | 31.03 | | 165 |
| 1 year | 25.1 | | 165 |
| 3 years | 25.1 | | 165 |
| 5 years | 25.1 | | 371.14 |
| 10 years | 25.1 | | 371.14 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 2011-02-28 |
James Mock
DFI | Director of Finance/CFO | 49 | 2022-09-05 |
Stephen Hoge
PSD | President | 50 | 2024-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 2012-01-31 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 2011-02-28 |
Francois Nader
BRD | Director/Board Member | 69 | 2019-12-10 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.66% | +5.77% | - | - | 57.4B | |
| +0.06% | -4.09% | +34.70% | -5.93% | 77.3B | |
| +1.23% | +4.39% | -12.00% | -33.40% | 59.52B | |
| +1.29% | +7.38% | +486.23% | +27.08% | 57.4B | |
| -0.21% | -2.96% | -11.54% | +25.36% | 47.91B | |
| -1.81% | +0.73% | +1.08% | +144.77% | 46.2B | |
| -0.07% | +2.51% | +50.34% | -15.22% | 31.94B | |
| +2.47% | -1.00% | +48.69% | +99.44% | 24.68B | |
| -0.95% | -4.18% | -2.23% | +140.05% | 21.08B | |
| -0.05% | -0.86% | +57.38% | +95.99% | 15.65B | |
| Average | -0.06% | -0.13% | +72.52% | +53.13% | 42.41B | |
| Weighted average by Cap. | -0.12% | -0.01% | +86.55% | +35.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.82B 1.72B 1.56B 2.93B 202B 2.95B 20.54B 7.94B 102B 7.89B 7.72B 326B | 2.44B 2.11B 2B 1.81B 3.4B 234B 3.42B 23.84B 9.21B 119B 9.16B 8.96B 378B |
| Net income | -3.31B -2.87B -2.71B -2.46B -4.62B -318B -4.64B -32.39B -12.52B -161B -12.44B -12.17B -514B | -1.94B -1.69B -1.59B -1.45B -2.71B -187B -2.73B -19.01B -7.35B -94.62B -7.3B -7.14B -302B |
| Net Debt | -3.65B -3.17B -2.99B -2.72B -5.09B -350B -5.12B -35.72B -13.8B -178B -13.72B -13.42B -567B | -2.17B -1.88B -1.78B -1.61B -3.02B -208B -3.04B -21.22B -8.2B -106B -8.15B -7.97B -337B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-10 | US$145.35 | +8.61% | 41 |
| 26-09-16 | US$146.60 | +1.17% | 267 |
| 26-09-15 | US$144.90 | -1.70% | 835 |
| 26-09-14 | US$147.41 | +1.42% | 599 |
| 26-09-11 | US$145.35 | +8.61% | 41 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
- MRNA_KZ Stock
Select your edition
All financial news and data tailored to specific country editions
